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Background: Although sarcoidosis most commonly affects the lungs, it is a multisystemic dis-
ease that often involves other organs. In this study, we compared fatigue, dyspnea, and the
impact upon the activities of daily living and health status scores between patients with iso-
lated pulmonary and pulmonary plus extrapulmonary sarcoidosis.
Methods: In this cross-sectional study, we investigated 81 biopsy proven sarcoidosis patients.
Fatigue was assessed by the standardized Fatigue Scale (FS). Dyspnea was determined by
the Baseline Dyspnea Index (BDI) and the Modified Medical Research Council (MRC) Dyspnea
Scale. Activities of daily living were assessed with the List of Daily Activities (DAL). Health sta-
tus was measured by two standardized questionnaires: a generic measure e fifteen-dimen-
sional measure of health-related quality of life (15D), and a respiratory-specific measure e
St George’s Respiratory Questionnaire (SGRQ). Patients were excluded if they had an associ-
ated illness that could influence their health status.
Results: Statistically significant differences were demonstrated between the isolated pulmo-
nary group and the pulmonary plus extrapulmonary group for fatigue (FSetotal score:
2.4  0.64 vs. 2.8  0.62, pZ 0.007), dyspnea (BDI: 8.45  2.44 vs. 5.92  1.84, p< 0.001;
there was no statistically significant difference in MRC), activities of daily livingl etiology of sarcoidosis study; BDI, Baseline Dyspnea Index; DAL, List of Daily Activities; FS, Fatigue
h Council Dyspnea Scale; SGRQ, The St George’s respiratory questionnaire; 15D, Fifteen-dimensional
life.
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Patient reported outcomes in sarcoidosis patients 1637(DAL: 4.33  2.93 vs. 5.87  2.40, pZ 0.014), and health status (SGRQe total score:
33.07 22.81 vs. 43.69 21.55, pZ 0.04).
Conclusion: There are significant and clinically relevant differences in the severity of symp-
toms, restrictions of activities of daily living and impairment of health status between the
patients with isolated pulmonary and pulmonary plus extrapulmonary sarcoidosis. Patients
with pulmonary plus extrapulmonary sarcoidosis are more impaired in all these categories.
ª 2008 Elsevier Ltd. All rights reserved.Introduction
Sarcoidosis is a chronic multisystemic disease that is most
commonly present in the lungs but may involve any
organ.1,2
Patients with pulmonary sarcoidosis may have symptoms
related directly to the chest such as cough, dyspnea on
exertion, chest pain, chest discomfort, and wheeze.
Patients may also develop symptoms related to extrapul-
monary organ involvement. In addition, sarcoidosis may
cause constitutional symptoms such as fever, anorexia,
weight loss, generalized weakness, fatigue, and pain that
are not attributable to involvement of any specific organ.
Fatigue is a major concern of sarcoidosis patients that
influences their health status and the quality of life.3,4
Health status is a subjective parameter that is being
used more frequently to assess health interventions.
Questionnaires have been developed, both generic and
disease-specific, to assess health status.
Differences in patients reported outcomes between
sarcoidosis patients with isolated pulmonary involvement
and those with extrapulmonary manifestations have not
been well described. We hypothesized that sarcoidosis
patients with pulmonary plus extrapulmonary involvement
would have more severe fatigue, be more limited in
activities of daily living and have a more severe impairment
in health status. However, we expected dyspnea to be
similar in those with isolated pulmonary involvement and
those with pulmonary plus extrapulmonary involvement.
The aim of this study was to assess the differences of the
severity of fatigue and dyspnea symptoms, activities of
daily living and health status between the patients with
isolated pulmonary and those with pulmonary plus extrap-
ulmonary sarcoidosis.
Methods
This cross-sectional study was conducted at the Institute for
LungDiseases andTuberculosis of the Clinical Center of Serbia
in Belgrade over the period fromOctober 2006 to March 2007.
We examined 81 consecutive patients with biopsy proven
pulmonary sarcoidosis. They all had noncaseating epithelioid
cell granulomas on their lung biopsy specimens without
a known cause being identified. All subjects were 18 years
old, and did not have any associated illnesses that could
influence their health status (those with significant comor-
bidity, like cardiac or respiratory disorders, were excluded
fromanalysis). Subjectswho did not understand the questions
from any of the symptoms or health status administered
questionnaires were also excluded.We classified patients into two groups according to the
organs affected by sarcoidosis. The first group consisted of
patients with isolated pulmonary involvement. The second
group consisted of patients who in addition to pulmonary
involvement had extrapulmonary sarcoidosis in one or more
additional organs on the basis of clinical, radiographic or
pathologic criteria. The investigators who classified the
patients as having isolated pulmonary or pulmonary plus
extrapulmonary sarcoidosis had extensive clinical experi-
ence with the diagnosis and clinical management of
sarcoidosis patients.
Study subjects underwent a physical examination, pul-
monary function testing, and completed questionnaires for
fatigue, dyspnea, activities of daily living, and health status
measurement. This study was approved by the institution’s
institutional review board and patients’ consent obtained.
Fatigue measurement
Fatigue was assessed by the standardized Fatigue Scale.5
This scale contains 14 questions and distinguishes mental
fatigue (with six items) that describes cognitive difficulties,
and physical fatigue (eight items). A total fatigue score is
also calculated. Each fatigue score ranges from 1 to 4.
Higher scores correspond with more severe fatigue. The
scale was found to be both reliable and valid5 and has
shown sensitivity to treatment changes.6
Dyspnea questionnaires
Dyspnea was measured by two standardized questionnaires:
the Baseline Dyspnea Index (BDI)7 and the Modified Medical
Research Council (MRC) Dyspnea Scale.8
The BDI partitions dyspnea into three components:
degree of the functional impairment, level of the activity,
and the level of effort required to develop dyspnea. Each
component is graded on a five-point rating scale from 0
(‘extreme impairment’) to 4 (‘without impairment’); there-
fore the total BDI score can range from 0 to 12.
The MRC scale classifies subjects into one of five
categories according to their degree of dyspnea when
performing certain activities.8 Scores range from 0 to 4,
with the higher scores indicating more severe dyspnea.
Activities of daily living
The degree of limitation in activities of daily living was
evaluated with the List of Daily Activities (DAL), a scale
that was originally designed by Stewart and coworkers.9 It
has 11 items that are related to the usual activities that
Table 1 Characteristics of patients (NZ 81), symptoms
and health status scores
X SD Range
Sex, m/f 20/61
Age, years 48.15 11.25 18e70
Disease duration, years 14.81 8.08 1e40
FEV1 (% predicted) 106.88 18.58 71e153
Fatigue scores
FSeTS 2.56 0.66 1.07e4
FSePS 2.65 0.73 1e4
FSeMS 2.43 0.72 1e4
Dyspnea scores
BDI 7.39 2.53 2e12
MRC 1.35 1.10 0e4
DAL 4.92 2.82 0e9
SGRQ
Total score 37.43 22.77 0e90.51
Symptoms 39.32 24.03 0e90.40
Activities 46.37 26.32 0e100
Impacts 31.73 24.40 0e93.02
15D 0.76 0.16 0.31e1.00
NZ number of patients; XZmean; SDZ standard deviation;
FSeTSZ Fatigue Scaleetotal score; FSePSZ Fatigue Scalee
physical component score; FSeTSZ Fatigue Scaleemental
component score; BDIZ Baseline Dyspnea Index; MRCZModi-
fied Medical Research Council Dyspnea Scale; DALZ List of
Daily Activities; and SGRQZ The St George’s Respiratory
Questionnaire.
1638 B.S. Gvozdenovic et al.persons with good health can perform without particular ef-
fort. The number of positive responses comprises the DAL
score and indicates the degree of impairment. The scale
has been used in several studies in patients with chronic
pulmonary diseases.10
Patient health status
We used two standardized questionnaires for the measuring
of health status: a generic measure e the fifteen-dimen-
sional measure of health-related quality of life (15D)11
and a respiratory-specific measure e the St George’s Respi-
ratory Questionnaire (SGRQ).12
15D is a multiattributive instrument for measurement of
health-related quality of life.11 It was developed and vali-
dated in a large Finnish population. It consists of 15 differ-
ent and mutually exclusive health dimensions, each
represented by one item.13,14 The total questionnaire score
ranges between 0 and 1, where 1 signifies the highest level
of health status. 15D was used in different diseases in many
different countries. The Serbian version of 15D was previ-
ously used in patients with asthma where it demonstrated
good psychometric measurement properties.15
SGRQ is an instrument that was originally designed to
measure the health status of COPD patients.12 Its valid-
ity, reliability, and responsiveness were also shown in
other pulmonary diseases. The questionnaire consists of
50 items with 76 responses, and encompasses three
domains of health status: (1) symptoms, focusing on dis-
tress because of respiratory symptoms, (2) activities,
measuring decreased mobility or physical activity and
(3) impacts, measuring the psychosocial influence of dis-
ease on the everyday life and patients’ well being. Scores
of these domains, as well as the total score, are scaled
from 0 to 100, where higher scores represent poorer
health status.
Pulmonary function
Pulmonary function measurements included forced expira-
tory vital capacity (FVC), forced expiratory volume in 1 s
(FEV1), peak expiratory flow (PEF) measured with a pneu-
motachograph (Masterlab, Jaeger, Wurzburg, Germany),
and total lung capacity (TLC) measured using the helium
dilution technique (Masterlab, Jaeger, Wurzburg,
Germany). The transfer factor of the lung for carbon mon-
oxide (TLCO) was measured using the single-breath method
(Masterlab, Jaeger, Wurzburg, Germany).
Statistical analysis
Statistical analysis was performed using the standard
computer statistical package (‘‘SPSS 10.0 for Windows’’,
1999). Values were expressed as mean 1 standard
deviation (SD). Differences of mean values of clinical
variables (symptoms, activities of daily living and health
status scores) between patients groups were measured
by means of t-Test for independent samples. A probabil-
ity value of p< 0.05 was considered to be statistically
significant, and p< 0.01 highly statistically significant.Results
The demographic characteristics, forced expiratory volume
in 1 s (FEV1) predicted, symptoms, activities of daily living
and health status scores of the study patients are presented
in Table 1. The average disease duration was 14.8 years,
and mean value of FEV1 was 106.9 18.6% predicted.
The total time required to complete the fatigue and
dyspnea questionnaires, DAL and health status question-
naires ranged from 30 to 45 min. Patients’ positive
responses on the DAL are presented in Table 2. More than
half patients gave affirmative answers to 7 out of 11 items
on DAL scale. These results show that most sarcoidosis
patients had significant impairment in their activities of
daily living despite the fact that most had normal spirome-
try (Table 1).
There were 49 patients with isolated pulmonary
involvement and 32 patients with pulmonary plus extrap-
ulmonary sarcoidosis (Table 3). There was no significant
difference in age or gender frequency between the pulmo-
nary and pulmonary plus extrapulmonary groups (Table 3).
The frequencies of the extrapulmonary organ involvement
with sarcoidosis are presented in Fig. 1. The skin and
neurologic system were the most frequent locations of
extrapulmonary disease.
A statistically significant difference was found between
the average of all fatigue scores, BDI scores, DAL scores,
and total and activity domain SGRQ scores with regard to
Table 2 Percentage of patient positive responses on the List of Daily Activities Questions (NZ 78)
Questions Affirmative
responses, %
1 Do you need help with eating, dressing, bathing, or using the lavatory
because of your health?
3.8
2 Are you in bed or a chair for most or all of the day because of your health? 1.3
3 When you travel around in our community, does someone have to assist
you because of your health?
15.4
4 Do you have to stay indoors most or all of the day because of your health? 25.6
5 Does your health keep you from working at a job or doing work around the house? 53.8
6 Are you unable to do certain kinds or amounts of work or housework or do you have
to work part-time because of your health?
64.1
7 Do you have any trouble either walking one block or climbing one flight of stairs
(without shopping bags) because of your health?
50
8 Do you have troubles bending, lifting, or stooping because of your health? 62.8
9 Does your health limit you in any way from doing anything you want to do? 71.8
10 Does your health limit the kind of vigorous activities you can do, such as running
or lifting heavy objects?
82.1
11 Do you have any trouble either walking several blocks or climbing a few
flights of stairs (without shopping bags), because of your health?
61.5
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ulmonary group was more impaired than the isolated
pulmonary group (Table 4). Differences between symp-
toms and impacts domain SGRQ scores, MRC dyspnea
scores and 15D scores did not reach the statistical
significance.
We did not find a significant difference of any
pulmonary function parameter between the patients
with isolated pulmonary and pulmonary plus extrapulmo-
nary sarcoidosis (Table 3).Table 3 Demographs and pulmonary function tests’ values of pa
monary sarcoidosis
X SD,
pulmonary
sarcoidosis group
N 49
Sex, m/f (%)a 16/33 (33/67)
Age, years 47.78 11.18
Spirometry tests
FVC (L) 3.80 1.03
FVC (% predicted) 110.96 17.93
FEV1 (L) 3.06 0.95
FEV1 (% predicted) 105.73 18.56
PEF (L/s) 8.47 3.17
PEF (% predicted) 116.69 24.35
TLC (L) 5.39 1.11
TLC (% predicted) 98.38 13.13
TLCO (mmol/min/kPa) 7.54 2.19
TLCO (% predicted) 86.04 14.27
NZ number of patients; XZmean; SDZ standard deviation; and tZ
a Chi-square test value 3.214, p> 0.05.Discussion
The present study showed that sarcoidosis patients with
pulmonary and extrapulmonary manifestations of sarcoid-
osis are more fatigued, more dyspneic, have poorer health
status, and more impairment of activities of daily living
than those with pulmonary involvement alone.
Fatigue is a common symptom of sarcoidosis. It has been
hypothesized that fatigue from sarcoidosis is caused by
inflammatory mediators released from the granulomatoustients with isolated pulmonary and pulmonary plus extrapul-
X SD,
pulmonary plus
extrapulmonary
sarcoidosis group
t p
32
4/28 (12/88)
48.41 11.56 0.243 0.809
3.84 1.13 0.143 0.887
116.50 13.97 1.549 0.125
3.02 1.02 0.199 0.843
108.59 18.76 0.672 0.504
7.49 1.90 1.572 0.120
110.84 19.77 1.179 0.242
5.42 1.13 0.127 0.899
103.22 11.72 1.725 0.089
7.29 1.71 0.568 0.572
85.69 15.11 0.105 0.917
t-Test for independent samples.
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Figure 1 Extrapulmonary sarcoidosis e % of all 81 patients.
1640 B.S. Gvozdenovic et al.inflammation.16 Pain also appears to be related to fatigue
in sarcoidosis.17 Pain itself and the resultant lack of mobil-
ity from pain may also contribute to fatigue. In addition,
fatigue and depression may occur with sarcoidosis involve-
ment of the central nervous system,18 which was a frequent
extrapulmonary manifestation in our patient population
(12.3%). Pain, lack of mobility, depression, and central ner-
vous system involvement with sarcoidosis might explain
why fatigue was more severe in those patients with pulmo-
nary and extrapulmonary sarcoidosis than in the group with
isolated pulmonary involvement. However since pain, lack
of mobility, and depression were not measured in this
study, this postulation remains conjectural.Table 4 Differences between symptoms, activities of daily livin
monary (NZ 49) and pulmonary plus extrapulmonary sarcoidosis
X SD,
pulmonary
sarcoidosis group
X
p
e
s
Fatigue scores
FSeTS 2.40 0.64
FSePS 2.47 0.72
FSeMS 2.31 0.65
Dyspnea scores
BDI 8.45 2.44
MRC 1.13 1.26
DAL 4.33 2.93
SGRQ
Total score 33.07 22.81 4
Symptoms 37.32 26.21 4
Activities 40.17 26.46 5
Impacts 27.69 23.83 3
15D 0.78 0.17
NZ number of patients; XZmean; SDZ standard deviation; tZ t-Te
FSePSZ Fatigue Scaleephysical component score; FSeTSZ Fatigue
MRCZModified Medical Research Council Dyspnea Scale; DALZ Li
Questionnaire.The DAL measures the ability to perform various daily
activities such as eating, dressing, bathing, using the
lavatory, walking, and climbing. These activities could be
influenced by many extrapulmonary organs that are
commonly affected by sarcoidosis including the nervous
system, skin, and bones. This could explain our findings that
the activities of daily living were more impaired in the
pulmonary plus extrapulmonary group compared to the
isolated pulmonary group.
Health status is a broad concept that is influenced by
numerous factors including many extrapulmonary ones. It is
likely that constitutional symptoms of sarcoidosis and
extrapulmonary organ involvement contributed tog and health status scores between patients with isolated pul-
(NZ 32)
 SD,
ulmonary plus
xtrapulmonary
arcoidosis group
t p
2.80 0.62 2.797 0.007
2.93 0.66 2.924 0.005
2.63 0.79 2.015 0.047
5.92 1.84 4.479 <0.000
1.67 1.07 1.844 0.070
5.87 2.40 2.405 0.014
3.69 21.55 2.090 0.040
2.19 20.56 0.880 0.382
5.27 23.77 2.633 0.010
7.55 24.39 1.772 0.081
0.73 0.13 1.637 0.106
st for independent samples; FSeTSZ Fatigue Scaleetotal score;
Scaleemental component score; BDIZ Baseline Dyspnea Index;
st of Daily Activities; and SGRQZ The St George’s Respiratory
Patient reported outcomes in sarcoidosis patients 1641functional limitation and consequently had an important
influence on health status. It is therefore not surprising that
health status is more impaired in the pulmonary plus
extrapulmonary group of sarcoidosis patients compared to
those with isolated pulmonary involvement.
Our results showed that those with pulmonary plus
extrapulmonary sarcoidosis had statistically and clinically
significant worse health status in terms of SGRQ score than
those with isolated pulmonary sarcoidosis. This is an
interesting finding since the SGRQ is a respiratory-specific
questionnaire. One possible explanation for this is that
several items of the questionnaire relate to physical
activities and the impact of disease on the patients’ level
of functioning. It is possible that extrapulmonary manifes-
tations of sarcoidosis negatively impacted upon these
items. The 15D, a generic measure of health status, did
not show a statistically significant difference between the
isolated pulmonary and pulmonary plus extrapulmonary
groups, although the mean score reflected poorer health
status in the latter group. The total SGRQ score (mean
score SD: 37.4 22.8) of our patients was comparable
with a previous study of chronic sarcoidosis patients by
Cox et al. (44 23).19 The total SGRQ mean score in our
patients was somewhat less than the mean score (46, stan-
dard deviation not reported) in the recently published
study by Baughman and coworkers.20 However, their study
population had a higher frequency of extrapulmonary
involvement (73%), as compared to our patients (39.5%).
This difference in the frequency of extrapulmonary sarcoid-
osis between the two studies probably explains the differ-
ences in the SGRQ scores.
We expected dyspnea to be similar in those with isolated
pulmonary involvement and those with pulmonary plus
extrapulmonary involvement. However, we found that
dyspnea was more severe in the latter group. This was
demonstrated using the BDI measure but not the MRC.
Unlike the BDI, the MRC only addresses the level of
activities that leads to dyspnea without consideration of
the associated effort necessary for the performance of
particular activity.21 Furthermore, only the BDI assesses the
degree of the functional impairment, which represents an
important consequence of dyspnea. Since the patients’ per-
ception of dyspnea depends on the physical activities and
effort they require in order to feel the breathless, those
patients who have involvement of both lungs and other
organ(s) may be more dyspneic because they are more
functionally limited.
Although our patients were fatigued, had significant
dyspnea, perceived limitations in their physical activities,
and had a poor health status, they had normal pulmonary
function. This confirms previous studies demonstrating that
pulmonary function testing cannot function as a surrogate
for these other parameters and cannot be used to assess
the overall health of sarcoidosis patients.22,23
One limitation of this study is that the data were
collected in a tertiary care setting, i.e. a specialised
referral clinic for sarcoidosis patients. Based on the clinical
and radiographic criteria (62.2% of the patients had
radiographic stage 2 or higher), our patients had pre-
dominantly severe forms of the disease and the scores for
all patient reported outcomes were probably more severe
than for the average sarcoidosis patient. Therefore, ourresults may not be generalizable to patients in primary care
settings. In addition, 80.5% of our study patients were
receiving corticosteroid therapy, and this may have had
a positive or negative impact upon their health status and
other measured variables. Although we excluded subjects
from this study with severe overt comorbidity, our results
may have also been affected by unmeasured comorbidities.
Finally, our criteria for the presence of extrapulmonary
sarcoidosis were not standardized. We used clinical, radio-
graphic, and pathologic criteria to define subjects as having
extrapulmonary involvement. Although this classification is
arguably subjective, it was performed by individuals with
expertise in the clinical assessment of sarcoidosis patients
(B.S.G., V.M.V.). Furthermore even a standardized measure
of organ involvement such as the A Case Control Etiology of
Sarcoidosis Study (ACCESS) instrument24 relies somewhat
upon the subjective clinical judgment of the assessor. In ad-
dition, the assignment of subjects in the two groups was
made a priori so that it should not have influenced the study
results.
We conclude that patients with pulmonary and extrap-
ulmonary sarcoidosis are more fatigued, have more dysp-
nea, are more limited in their everyday physical activities,
and have lower health status in comparison with those with
isolated pulmonary involvement. We propose several mech-
anisms to explain these differences. However, our expla-
nations remain conjectural and are potential fruitful areas
for future research.
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